Apyx Medical Corp: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 10, 2020 and accepted by EDGAR at Aug 10, 2020, 09:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $4.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $9.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $2.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $2.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2020-01-01 to 2020-06-30 | $5.1m | us-gaap:GrossProfit |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $975.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-04-01 to 2020-06-30 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2020-01-01 to 2020-06-30 | $6.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$6.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$13.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $8.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $14.0k | us-gaap:InterestExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | −$1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | −$6.4m | us-gaap:IncomeTaxExpenseBenefit |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$12.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $184.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $46.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $69.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $77.8m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $9.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $11.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $66.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-20-000057. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.